Medtronic (MDT) Change in Accured Expenses (2014 - 2026)

Medtronic (MDT) has 13 years of Change in Accured Expenses data on file, last reported at $123.0 million in Q2 2026.

• For the quarter ending Q2 2026, Change in Accured Expenses fell 66.39% year-over-year to $123.0 million; the trailing twelve-month figure through Apr 2026 stood at $46.0 million (down 77.99% YoY), and the FY2026 full-year result was $46.0 million, down 77.99% from the prior year.
• Change in Accured Expenses slipped to $123.0 million in Q2 2026, from $703.0 million in the prior quarter.
• In the past five years, Change in Accured Expenses ranged from a high of $703.0 million in Q1 2026 to a low of -$673.0 million in Q3 2023.
• A 5-year average of $111.2 million and a median of $155.0 million in 2022 frame the typical range for Change in Accured Expenses.
• Across the five-year window, Change in Accured Expenses jumped 10250.0% in 2022 and slumped 357.82% in 2023, its largest moves.
• Tracing MDT's Change in Accured Expenses over 5 years: stood at $133.0 million in 2022, then tumbled by 119.55% to -$26.0 million in 2023, then sank by 296.15% to -$103.0 million in 2024, then slumped by 76.7% to -$182.0 million in 2025, then soared by 167.58% to $123.0 million in 2026.
• Business Quant data shows MDT's Change in Accured Expenses at $123.0 million in Q2 2026, $703.0 million in Q1 2026, and -$182.0 million in Q4 2025.